Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing drugs for developing countries.

David B Ridley1, Henry G Grabowski, Jeffrey L Moe

  • 1Fuqua School of Business, Duke University, Durham, North Carolina, USA. david.ridley@duke.edu

Health Affairs (Project Hope)
|March 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FDA Global Drug Inspections: Surveillance Of Manufacturing Establishments Remains Well Below Pre-COVID-19 Levels.

Health affairs (Project Hope)·2023
Same author

Consequences of a shortage and rationing: Evidence from a pediatric vaccine.

Journal of health economics·2023
Same author

​US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access.

Health affairs (Project Hope)·2021
Same author

A Voucher System To Speed Review Could Promote A New Generation Of Insecticides To Fight Vector-Borne Diseases.

Health affairs (Project Hope)·2017
Same author

Real-World Data: Responses to Zito and Doshi.

Medical care·2016
Same author

Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products.

Transfusion·2016
Same journal

National Health Expenditure Projections, 2025-34: Strong Utilization Growth Initially, Legislative Impacts Later.

Health affairs (Project Hope)·2026
Same journal

State Medicaid Programs Face Increased Spending On Medicare Premiums.

Health affairs (Project Hope)·2026
Same journal

Not enough time.

Health affairs (Project Hope)·2026
Same journal

Medicaid Tobacco And Nicotine Cessation Treatment Rates Remained Low, 2019-24.

Health affairs (Project Hope)·2026
Same journal

Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs.

Health affairs (Project Hope)·2026
Same journal

The Opacity Of Price Transparency.

Health affairs (Project Hope)·2026
See all related articles

Developing treatments for neglected infectious diseases could be accelerated by a priority review voucher. This FDA voucher incentivizes drug development and benefits global health.

Area of Science:

  • Global Health
  • Pharmaceutical Policy
  • Drug Development

Background:

  • Infectious and parasitic diseases disproportionately affect impoverished populations, leading to underinvestment in treatment development.
  • Neglected diseases represent a significant global health burden with limited therapeutic options.

Purpose of the Study:

  • To propose a "priority review voucher" system to incentivize the development of treatments for neglected diseases.
  • To explore the economic and public health benefits of such a voucher program.

Main Methods:

  • The study proposes a market-based incentive mechanism: a priority review voucher.
  • This voucher would expedite U.S. Food and Drug Administration (FDA) review for new treatments.
  • The voucher could be sold to manufacturers of other drugs, creating a revenue stream for developers of neglected disease treatments.

Related Experiment Videos

Main Results:

  • The proposed voucher system could significantly reduce drug review times, potentially saving an average of one year.
  • A well-functioning market for these vouchers would facilitate faster access to valuable treatments.
  • The initiative offers a cost-effective approach to improving health outcomes in both developing and developed nations.

Conclusions:

  • Priority review vouchers represent a viable and cost-effective strategy to stimulate investment in neglected disease therapeutics.
  • This policy innovation could address critical unmet medical needs and improve global health equity.
  • The program has the potential to benefit consumers worldwide while minimizing taxpayer burden.